#1 - The Oncology Institute (NASDAQ:TOI)
As its name implies, The Oncology Institute, Inc. (NASDAQ: TOI) is involved with many facets of cancer treatment. The company focuses on “value-based oncology care” and has three business units: dispensary, patient services, clinical trials and others. It goes without saying that the company has a large addressable market, as almost anybody reading this knows of one or more people that have been touched by cancer.
The company was founded in 2007 but has only been trading publicly since 2020. It was one of many companies that went public via a special purpose acquisition company (SPAC). These stocks lost favor with investors in late 2021, and that sent TOI stock tumbling. However, it wasn’t until March 2023 before it became a true penny stock.
TOI is partnering with the artificial intelligence firm, Massive Bio to help the company evaluate patient eligibility for its active clinical trial portfolio in addition to other services. Because the stock is a penny stock, it’s not widely covered by analysts. MarketBeat analyst ratings for the stock show two analysts that give the stock a price target of $6.50, which is a gain of over 950%.
However, a better barometer may be that 70% of institutional investors own 70% of the company’s stock. That's uncommon for a penny stock, and that should add stability and the opportunity for growth.
About Oncology Institute
The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.
Read More - Current Price
- $0.13
- Consensus Rating
- Buy
- Ratings Breakdown
- 1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $2.50 (1,839.5% Upside)
